# Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas

> **NCT04656730** · PHASE4 · COMPLETED · sponsor: **Hospital Vall d'Hebron** · enrollment: 68 (actual)

## Conditions studied

- Irritable Bowel Syndrome
- Functional Dyspepsia

## Interventions

- **DRUG:** Iberogast® and Iberogast® N

## Key facts

- **NCT ID:** NCT04656730
- **Lead sponsor:** Hospital Vall d'Hebron
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-03
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656730, "Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04656730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*